Harold J Burstein MD PhD and Lisa A Carey MD on Innovations in Triple Neg BC

Jack Cuzick, PhD, of the Wolfson Institute of Preventive Medicine, discusses abstract S3-07, "16-year long-term follow-up of the IBIS-I breast cancer prevention trial."

Breast Cancer

Ann H. Partridge, MD, MPH

Ann H. Partridge, MD, MPH, on Patient-Reported Outcomes From the SOFT Trial

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, on abstract S3-09, “Patient-reported endocrine symptoms, sexual functioning and quality of life in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen alone vs tamoxifen plus ovarian function suppression in premenopausal women with hormone receptor–positive early breast cancer.”

Breast Cancer

Larry Wickerham, MD, and Harry D. Bear, MD, PhD

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials:

•          B-40, the only study to combine neoadjuvant and adjuvant chemotherapy with bevacizumab
•          B-51, on radiation to the chest wall
•          Alliance trial, on lymph node dissection

Breast Cancer

Hope S. Rugo, MD

Hope S. Rugo, MD, on Dietary Intervention as Adjuvant Breast Cancer Therapy

Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S5-08, “Final survival analysis from the randomized Women's Intervention Nutrition Study (WINS) evaluating dietary intervention as adjuvant breast cancer therapy,” presented by Rowan T. Chlebowski, MD.

Breast Cancer

Lisa A. Carey, MD

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

Related Videos

Jack Cuzick, PhD, on the IBIS-I Trial

Ann H. Partridge, MD, MPH, on Patient-Reported Outcomes From the SOFT Trial

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

Hope S. Rugo, MD, on Dietary Intervention as Adjuvant Breast Cancer Therapy

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Two Decades of Collaboration: The Accelerating Anticancer Agent Development and Validation (AAADV) Workshop

Two Initiatives Could Help Increase Oncogene Testing in Primary Care Settings

Liquid Biopsies Could Help Guide Colorectal Cancer Treatment

Addition of ADT to SBRT in Hormone-Sensitive Oligorecurrent Prostate Cancer

Cancer Incidence and Mortality in Southeast Asia for 2022